The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ Transplantation
Open accessAbstract
BACKGROUND: The B-cell lymphoproliferative syndrome is an infrequent life-threatening complication of marrow or organ transplantation that is the consequence of profound immunosuppression. The results of treatment have been disappointing, although a small number of patients have been cured by chemoradiotherapy or antiviral agents after a reduction in the dosage of immunosuppressive therapy. We report here the results of treating this disorder with anti-B-cell antibodies. METHODS: Twenty-six patients in whom aggressive B-cell lymphoproliferative syndrome developed after bone marrow (n = 14) or organ (n = 12) transplantation received 0.2 mg of CD21-specific and of CD24-specific antibodies per kilogram of body weight for 10 consecutive days in an open, prospective, multicenter trial. RESULTS: The treatment was well tolerated. All patients had transient neutropenia, apparently because the CD24 molecule is also expressed on granulocytes. The treatment was ineffective in seven patients with monoclonal B-cell proliferation. In contrast, 16 patients with oligoclonal B-cell proliferation had complete remission. Systemic remission also occurred in two other patients with oligoclonal proliferation who had central nervous system involvement, although they subsequently died because of progression of the central nervous system disease. In one patient who died early, clonality was not determined. Of the 16 patients who had complete remission, 2 with persistent immunodeficiency due to graft (marrow) rejection or acute graft-versus-host disease had a relapse, and the 1 with graft-versus-host disease subsequently died. Eleven patients were alive and disease-free after a median follow-up of 35 months (5 of 14 marrow recipients and 6 of 12 organ recipients). Four other patients in complete remission died of unrelated causes 4 to 12 months after treatment. CONCLUSIONS: Intravenous administration of anti-B-cell antibodies may be effective in controlling diffuse, severe, oligoclonal B-cell proliferation not involving the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ford, R., & Eisenberg, S. (1990) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)02934-6 · Cited by 2,720
Starzl, T. E., Porter, K. A., Iwatsuki, S., Rosenthal, J. T., Shaw, B. W., Atchison, R. W., Nalesnik, M., Ho, M., Griffith, B. P., Hakala, T. R., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90994-2 · Cited by 1,234
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.
Fingeroth, J. D., Weis, J. J., Tedder, T. F., Strominger, J. L., Biro, P. A., & Fearon, D. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.14.4510 · Cited by 939
Young, L., Alfieri, C., Hennessy, K., Evans, H., O'Hara, C., Anderson, K. C., Ritz, J., Shapiro, R. S., Rickinson, A., Kieff, E., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198910193211604 · Cited by 749
Meyers, J. D., Reed, E. C., Shepp, D. H., Thornquist, M., Dandliker, P. S., Vicary, C. A., Flournoy, N., Kirk, L. E., Kersey, J. H., Thomas, E. D., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180202 · Cited by 442
BONE-MARROW TRANSPLANTATION FOR IMMUNODEFICIENCIES AND OSTEOPETROSIS: EUROPEAN SURVEY, 1968-1985
Fischer, A., Friedrich, W., Levinsky, R. J., Vossen, J. M. J. J., Griscelli, C., Kubanek, B., Morgan, G., Wagemaker, G., & Landais, P. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90477-0 · Cited by 193
Self-citationBONE MARROW TRANSPLANTATION: A REVIEW OF DELAYED COMPLICATIONS
Deeg, H. J., Storb, R. F., & Thomas, E. D. (1984) · British Journal of Haematology · doi:10.1111/j.1365-2141.1984.tb02887.x · Cited by 159
Pirsch, J. D., Stratta, R. J., Sollinger, H. W., Hafez, G. R., D'Allesandro, A. M., Kalayoğlu, M., & Belzer, F. O. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90279-9 · Cited by 123
Jarry, A., Cerf–Bensussan, N., Brousse, N., Guy‐Grand, D., Muzeau, F., & Potet, F. (1988) · Gut · doi:10.1136/gut.29.12.1632 · Cited by 34
Schubach, W., Miller, G., & Thomas, E. D. (1985) · Blood · doi:10.1182/blood.v65.3.535.535 · Cited by 25
Cited by
Rooney, C. M., Ng, C. Y. C., Loftin, S., Smith, C. A., Li, C., Krance, R. A., Brenner, M. K., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91150-2 · Cited by 1,173
Papadopoulos, E. B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M. H., Castro-Malaspina, H., Childs, B. H., Gillio, A. P., Small, T. N., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301703 · Cited by 1,043
EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS
Paya, C. V., Fung, J. J., Nalesnik, M. A., Kieff, E., Green, M., Gores, G., Habermann, T. M., Wiesner, R. H., Swinnen, L. J., Woodle, E. S., et al. (1999) · Transplantation · doi:10.1097/00007890-199911270-00015 · Cited by 533
Post-Transplant Lymphoproliferative Disorders
Gottschalk, S., Rooney, C. M., & Heslop, H. E. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104727 · Cited by 489
Ho, V. T., & Soiffer, R. J. (2001) · Blood · doi:10.1182/blood.v98.12.3192 · Cited by 426
Metadata
- Authors
- Fischer, A., Blanche, S., Le Bidois, J., Bordigoni, P., Garnier, J. L., Niaudet, P., Morinet, F., Le Deist, F., Fischer, A.-M., Griscelli, C., & Hirn, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1991-05-23
- Volume
- 324
- Issue
- 21
- Pages
- 1451-1456
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2026689623
- Cited by
- 343
- References
- 10
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ Transplantation. https://app.cochat.ai/papers/10.1056/nejm199105233242102
- The paper
- Fischer, A., Blanche, S., Le Bidois, J., Bordigoni, P., Garnier, J. L., Niaudet, P., Morinet, F., Le Deist, F., Fischer, A.-M., Griscelli, C., & Hirn, M. (1991). Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ Transplantation. New England Journal of Medicine. https://doi.org/10.1056/nejm199105233242102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.